Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

NIH 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Melanoma 13Lymphoma 11Lymphoma, Follicular 10Breast Neoplasms 10Multiple Myeloma 9Prostatic Neoplasms 8Neoplasms, Plasma Cell 8Leukemia, Myeloid, Acute 7Colonic Neoplasms 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Leukemia 5Kidney Neoplasms 5Small Cell Lung Carcinoma 4Rectal Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lung Neoplasms 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4HIV Infections 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Acquired Immunodeficiency Syndrome 4Testicular Neoplasms 3

Interventions

dinutuximab 4sargramostim 3Topotecan 3Cyclophosphamide 3Colony-Stimulating Factors 3Vincristine 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Radiation 2Platinum 2Melphalan 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2Etoposide 2Doxorubicin 2Cisplatin 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1iberdomide 1Transurethral Resection of Bladder 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Ganglioneuroblastoma × sargramostim × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡